Clinical Trial Update: An Open-Label Study Following Oral Dosing of Seladelpar to Subjects With Primary Biliary Cholangitis (PBC) and Hepatic Impairment (HI) [Phase 1]

View source ↗

Summary

An open-label Phase 1 study evaluating oral dosing of seladelpar in adults with primary biliary cholangitis and hepatic impairment (compensated cirrhosis) has c…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Biliary Cholangitis
• Cirrhosis

Drugs mentioned

• Seladelpar (seladelpar)

Snippet

Sponsor: Gilead Sciences | Conditions: Primary Biliary Cholangitis, Compensated Cirrhosis | Phase 1 | Status: COMPLETED